Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,417
datasets available to search
ShareScore release 0.9.0
Dataset results
1,417 results for “triple negative breast cancer”
A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer
ClinicalTrials.gov study NCT03316586. IPD Sharing: NO. Countries: 1. Publications: 0.
Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT03106415. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01617668. IPD Sharing: Not stated. Countries: 12. Publications: 0.
Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy
ClinicalTrials.gov study NCT02422498. IPD Sharing: Not stated. Countries: 1. Publications: 0.
LY3023414 and Prexasertib in Metastatic Triple-negative Breast Cancer
ClinicalTrials.gov study NCT04032080. IPD Sharing: NO. Countries: 1. Publications: 0.
L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients
ClinicalTrials.gov study NCT02834403. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies
ClinicalTrials.gov study NCT04927884. IPD Sharing: NO. Countries: 1. Publications: 0.
Olaparib in Locally Advanced ER, PgR and HER2 Negative (Triple Negative) and in Locally Advanced Germline BRCA Mutation-positive Breast Cancer Patients
ClinicalTrials.gov study NCT02681562. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
ClinicalTrials.gov study NCT02513472. IPD Sharing: Not stated. Countries: 1. Publications: 0.
2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02624700. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04489940. IPD Sharing: YES. Countries: 6. Publications: 0.
Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
ClinicalTrials.gov study NCT00608972. IPD Sharing: NO. Countries: 1. Publications: 0.
Assessement of Potential Interest of [68Ga]Ga-PentixaFor PET/CT in Metastatic Triple Negative Breast Cancer Patients
ClinicalTrials.gov study NCT06962163. IPD Sharing: NO. Countries: 1. Publications: 0.
Neo-Adjuvant Study in Triple Negative Breast Cancer Patients
ClinicalTrials.gov study NCT01097642. IPD Sharing: NO. Countries: 1. Publications: 0.
Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT02984683. IPD Sharing: Not stated. Countries: 5. Publications: 0.
Phase II Study of Erlotinib, an EGFR Inhibitor in Metastatic EGFR-positive 'Triple Receptor-negative' Breast Cancer
ClinicalTrials.gov study NCT00739063. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01525966. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer
ClinicalTrials.gov study NCT04849364. IPD Sharing: NO. Countries: 1. Publications: 0.
Panitumumab, Gemcitabine and Carboplatin in Triple-Negative Metastatic Breast Cancer
ClinicalTrials.gov study NCT00894504. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer
ClinicalTrials.gov study NCT01745367. IPD Sharing: NO. Countries: 10. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.